3. Summit Therapeutics (NASDAQ:SMMT)
Stock Upside Potential: 42.05%
Year-to-Date Gain: 26.03%
Summit Therapeutics is gaining traction based on upcoming clinical catalysts tied to its lead oncology asset, ivonescimab. On April 21, analysts at Stifel reiterated a Buy rating and set a $45 price target, pointing to strong potential upside.
The key catalyst is the upcoming HARMONi-6 interim overall survival readout expected to be presented at ASCO 2026. The study has a 33% larger sample size compared to HARMONi-2 and focuses on all-squamous histology, offering broader clinical relevance. It evaluates ivonescimab against tislelizumab in non-small cell lung cancer.
Previous data from HARMONi-2 already showed promising results when compared against Pembrolizumab in advanced NSCLC patients. In parallel, partner Akeso is pursuing label expansion in China following interim analysis showing favorable trends over Pembrolizumab.
Ivonescimab is a bispecific antibody targeting PD-1 and VEGF, combining immune checkpoint inhibition with anti-angiogenesis. This dual mechanism could position it as a first-in-class therapy if clinical data continues to hold. The upcoming data release remains the primary driver for valuation expansion.
Click next to see the following stock...
